SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 23, 2003
PharmaNetics, Inc.
(Exact name of registrant as specified in its charter)
North Carolina
(State or other jurisdiction of incorporation)
| 0-25133 | 56-2098302 | |
| (Commission file Number) | (IRS Employer ID Number) |
| 9401 Globe Center Drive, Morrisville, North Carolina | 27560 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code 919-582-2600
NA
(Former name or former address, if changed since last report)
| Item 5. | Other Events. |
On October 23, 2003, PharmaNetics and Bayer Corporation reached an agreement to extend the term of their global distribution agreement for another year, from December 31, 2003 to December 31, 2004. Pursuant to the terms of the global distribution agreement, originally entered into in 1998, Bayer serves as the distributor of PharmaNetics’ products, including routine and specialty test cards, controls and analyzers. The prices charged to Bayer are variable based on purchase volumes. A copy of the amendment to the distribution agreement is filed as an exhibit to this report.
| Item 7. | Exhibits |
(c) Exhibits
| 10.41* |
Amendment #1 to Amended and Restated Distribution Agreement, dated October 23, 2003, by
and between the Company and Bayer Corporation. |
| * | Confidential Treatment Requested |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PHARMANETICS, INC. | ||||||||
| Date: October 28, 2003 |
/s/ John P. Funkhouser | |||||||
| John P. Funkhouser President and Chief Executive Officer | ||||||||